Excerpts from recent editorials in the United States and abroad:

Nov. 9

The Washington Post says TrumpRx isn’t the best way to lower prices

In a landmark deal announced Thursday, President Donald Trump negotiated dramatically lower costs for weight-loss drugs produced by pharmaceutical giants Eli Lilly and Novo Nordisk, which could benefit Medicare and Medicaid patients, as well as Americans paying out of pocket. But here’s the skinny: What the president negotiated should not be reserved for big companies that play his game.

GLP-1 medications, including Wegovy and Zepbound, currently have a list price of more than $1,000 for a month-long supply. Trump’s deal would bring that down to $350 on average, and as low as $50 for those who have a co-pay. That could benefit millions of Americans

See Full Page